1.Expert consensus on implementation strategy of awake prone positioning for non-intubated patients in China (2023).
Yuanyuan MI ; Zheyi CAI ; Jing LIU ; Fei TIAN ; Liping YANG ; Lei BAO ; Shanbing HOU ; Su GU ; Li LI ; Xueli ZHOU ; Yun XU ; Shumei ZHANG ; Xiaoxia FU ; Xiaodi LI ; Chuansheng LI ; Liang SUN ; Xiaohong ZHANG ; Hong QI ; Shiying YUAN ; Liqun ZHU ; Haiyan HUANG ; You SHANG
Chinese Critical Care Medicine 2023;35(4):337-351
The awake prone position plays an important role in the treatment of hypoxemia and the improvement of respiratory distress symptoms in non-intubated patients. It is widely used in clinical practice because of its simple operation, safety, and economy. To enable clinical medical staff to scientifically and normatively implement prone position for awake patients without intubation, the committees of consensus formulation, guided by evidence-based methodology and Delphi method, conducted literature search, literature quality evaluation and evidence synthesis around seven topics, including indications and contraindications, evaluation, implementation, monitoring and safety management, termination time, complication prevention and health education of awake prone position. After two rounds of expert letter consultation, Expert consensus on implementation strategy of awake prone positioning for non-intubated patients in China (2023) was formulated, and provide guidance for clinical medical staff.
Humans
;
Consensus
;
Prone Position
;
Wakefulness
;
China
;
Dyspnea
2.Intraocular pressure distribution and reference interval of high-altitude eye health screening population from Xining, Qinghai
Yiquan YANG ; Yunlan BAO ; Yunxiao SUN ; Yuan XIE ; Xialing WANG ; You LIU ; Yanling XIE ; Jie HAO ; Xiaoxia PENG ; Sujie FAN ; Shizheng WU ; Ningli WANG
Chinese Journal of Experimental Ophthalmology 2023;41(2):166-172
Objective:To investigate the distribution of intraocular pressure (IOP) in high-altitude population aged 18 years and over in Xining, Qinghai and establish the reference interval (RI) of IOP.Methods:A cross-sectional study was conducted in Xining, Qinghai Province at 2.271 km above sea level from September 2019 to May 2020.Ophthalmic examinations and IOP measurement were conducted among subjects from Physical Examination Center of Qinghai Provincial People's Hospital.The subjects who had been living in Xining without leaving for three months were enrolled.Ophthalmic examinations included vision examination, IOP measurement, slit-lamp microscopy, fundus photography, anterior and posterior segment optical coherence tomography.IOP was measured using Goldmann applanation tonometry under local anesthesia.Subjects with factors that could cause significant changes in IOP and affect the accuracy of IOP measurement, and those who were unable to receive IOP measurement were excluded.Subjects were grouped according to sex, age and ethnicity, and the distribution and RI of IOP were compared among all groups.This study adhered to the Declaration of Helsinki.The study protocol was approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University (No.TRECKY2017-024). Written informed consent was obtained from each subject.Results:A total of 6 120 subjects (6 120 eyes) aged 18-90 years old were enrolled, including 2 850 males and 3 270 females with average age of (45.54±13.85) years.The average IOP of high-altitude population in Xining, Qinghai Province was (14.32±1.93) mmHg (1 mmHg=0.133 kPa), with the RI of 10.54-18.10 mmHg.The average IOP was (14.42±1.98) mmHg in male with the RI of 10.54-18.30 mmHg, (14.23±1.88) mmHg in female with the RI of 10.55-17.91 mmHg.The IOP of male was higher than that of female ( t=3.71, P<0.001). The IOP of Han, Tibetan, Hui and other nationalities were (14.38±1.91), (13.93±2.06), (14.21±1.87), (13.94±1.95) mmHg, respectively, with a statistically significant overall difference ( F=6.73, P<0.001). The IOP of Han nationality was significantly higher than that of Tibetan, Hui and other nationalities, and the differences were statistically significant (all at P<0.05). Conclusions:RI of IOP in high-altitude population from Xining, Qinghai is lower compared with normal altitude area.
3.Gold nanoparticle-directed autophagy intervention for antitumor immunotherapy via inhibiting tumor-associated macrophage M2 polarization.
Siyue ZHANG ; Fangyuan XIE ; Kaichun LI ; He ZHANG ; You YIN ; Yuan YU ; Guangzhao LU ; Shihao ZHANG ; Yan WEI ; Ke XU ; Yan WU ; Hong JIN ; Lan XIAO ; Leilei BAO ; Can XU ; Yulin LI ; Ying LU ; Jie GAO
Acta Pharmaceutica Sinica B 2022;12(7):3124-3138
Tumor-associated macrophages (TAMs), one of the dominating constituents of tumor microenvironment, are important contributors to cancer progression and treatment resistance. Therefore, regulation of TAMs polarization from M2 phenotype towards M1 phenotype has emerged as a new strategy for tumor immunotherapy. Herein, we successfully initiated antitumor immunotherapy by inhibiting TAMs M2 polarization via autophagy intervention with polyethylene glycol-conjugated gold nanoparticles (PEG-AuNPs). PEG-AuNPs suppressed TAMs M2 polarization in both in vitro and in vivo models, elicited antitumor immunotherapy and inhibited subcutaneous tumor growth in mice. As demonstrated by the mRFP-GFP-LC3 assay and analyzing the autophagy-related proteins (LC3, beclin1 and P62), PEG-AuNPs induced autophagic flux inhibition in TAMs, which is attributed to the PEG-AuNPs induced lysosome alkalization and membrane permeabilization. Besides, TAMs were prone to polarize towards M2 phenotype following autophagy activation, whereas inhibition of autophagic flux could reduce the M2 polarization of TAMs. Our results revealed a mechanism underlying PEG-AuNPs induced antitumor immunotherapy, where PEG-AuNPs reduce TAMs M2 polarization via induction of lysosome dysfunction and autophagic flux inhibition. This study elucidated the biological effects of nanomaterials on TAMs polarization and provided insight into harnessing the intrinsic immunomodulation capacity of nanomaterials for effective cancer treatment.
4.Chinese Expert's Perspectives on Andrological Diseases Responding Specifically to Traditional Chinese Medicine
Yue-qing LI ; Hai-song LI ; Yong-zhang SUN ; Sheng LIN ; Bao-xing LIU ; Jia-you ZHAO ; Jian-wu SHEN ; Hong-ming LIU ; Jing-shang WANG ; Yuan TANG ; Shao-ming LIU ; Hai WANG ; Yu-tian ZHU ; Yong ZHU ; Yong YANG ; Xiao-xiao ZHANG ; Bin WANG
Chinese Journal of Experimental Traditional Medical Formulae 2021;27(12):182-188
In recent years, the incidence rate of andrological diseases has shown a significant growth trend. Considering the unavailability of a perfect theoretical system for andrology in traditional Chinese medicine (TCM) and the complex pathogenesis despite of the limited types of andrological diseases, it is necessary to improve the clinical efficacy of andrological diseases so as to satisfy the needs of patients. Therefore, the China Association of Chinese Medicine (CACM) organized the andrologists of TCM and western medicine and the outstanding young clinicians to discuss the andrological diseases responding specifically to TCM or integrated TCM and western medicine, such as chronic prostatitis, male infertility, benign prostatic hyperplasia, erectile dysfunction, and premature ejaculation, determine their diagnostic criteria in western medicine, and standardize the specifications for TCM diagnosis and treatment based on syndrome differentiation, thus formulating recognized and integrated diagnosis and treatment protocols. Apart from proposing suggestions on the treatment of such andrological diseases with TCM and western medicine, the experts have also figured out the andrological diseases responding specifically to TCM, the optimal intervention time of TCM and western medicine, and the suitable measures including surgery. The resulting consensus helps to better guide the formulation of accurate, personalized, and optimized treatment plans in clinical practice and improve the diagnosis and treatment effects of andrological diseases by giving full play to the advantages of TCM, which will in turn contribute to further innovation and development of TCM.
5.Expert consensus on prevention and management of enteral nutrition therapy complications for critically ill patients in China (2021 edition)
Yuanyuan MI ; Haiyan HUANG ; You SHANG ; Xiaoping SHAO ; Peipei HUANG ; Chenglin XIANG ; Shuhua WANG ; Lei BAO ; Lanping ZHENG ; Su GU ; Yun XU ; Chuansheng LI ; Shiying YUAN
Chinese Critical Care Medicine 2021;33(8):903-918
Enteral nutrition plays an irreplaceable role in the nutritional treatment of critically ill patients. In order to help clinical medical staff to manage the common complications during the implementations of enteral nutrition for critically ill patients, the consensus writing team carried out literature retrieval, literature quality evaluation, evidence synthesis. Several topics such as diarrhea, aspiration, high gastric residual volume, abdominal distension, etc. were assessed by evidence-based methodology and Delphi method. After two rounds of expert investigations, Expert consensus on prevention and management of enteral nutrition therapy complications for critically ill patients in China (2021 edition) developed, and provided guidance for clinical medical staff.
6.Application of DNA barcoding technology to national drug sampling inspection
Tian-yi XIN ; Hai-xia YAN ; Ran-jun LI ; Qian LOU ; Li-jun HAO ; Bao-sheng LIAO ; Ying LIU ; Jing CHEN ; You-gen CHEN ; Xiao-wei DU ; Hong-zhu GUO ; Xin-tong FU ; Jing-yuan SONG
Acta Pharmaceutica Sinica 2021;56(5):1497-1508
Adulterants and counterfeits were found in some of the commercial traditional Chinese medicine (TCM) decoctions in Hongjin Xiaojie Jiaonang, Hongjin Xiaojie Pian, and Chaihuang Keli during the national drug sampling inspection. However, it was difficult to determine the species of the adulterants and counterfeits by conventional testing methods. Therefore, a total of 184 samples of the TCM decoctions and raw materials belong to the prescriptions of above mentioned traditional Chinese patent medicines, including Bupleuri Radix, Bajiaolian, Heimayi, and Shufuchong, were collected and authenticated by DNA barcoding technology. 111 ITS2 sequences were obtained from 115 commercial TCM decoctions and raw materials of Bupleuri Radix, among which 71 were
7.Genetic profile of Chinese patients with Charcot-Marie-Tooth disease.
Zhi-Yuan OUYANG ; You CHEN ; Da-Qiang QIN ; Zhi-Dong CEN ; Xiao-Sheng ZHENG ; Fei XIE ; Si CHEN ; Hao-Tian WANG ; De-Hao YANG ; Xin-Hui CHEN ; Le-Bo WANG ; Bao-Rong ZHANG ; Wei LUO
Chinese Medical Journal 2020;133(21):2633-2634
8.Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase.
Yi Lin CHEN ; Long WANG ; Guo Lin YAN ; Zhuang Zhi YANG ; Zhi Ping HUANG ; You Shan ZHANG ; Zhe ZHAO ; Chu Cheng WAN ; Ying BAO ; Hang XIANG ; Hua YIN ; Li Feng CHEN ; Ying Yuan XIONG ; Li MENG ; Wei Ming LI
Chinese Journal of Hematology 2019;40(2):98-104
Objective: To investigate the efficiency and safety of domestic tyrosine kinase inhibitor (TKI) dasatinib (Yinishu) as second-line treatment for patients with chronic myeloid leukemia in chronic phase (CML-CP). Methods: A retrospective analysis of clinical data of CML-CP patients who received domestic dasatinib as second-line treatment in the CML collaborative group hospitals of Hubei province from March 2016 to July 2018 was performed. The optimal response rate, the cumulative complete cytogenetic response (CCyR), the cumulative major molecular responses (MMR), progression free survival (PFS), event free survival (EFS) and adverse effects (AEs) of the patients were assessed at 3, 6 and 12 months of treatment. Results: A total of 83 CML-CP patients were enrolled in this study. The median follow-up time was 23 months. The optimal response rates at 3, 6 and 12 months in 83 CML-CP patients treated with dasatinib were 77.5% (54/71), 72.6% (61/75) and 60.7% (51/69), respectively. By the end of follow-up, the cumulative CCyR and MMR rates were 65.5% (55/80) and 57.1% (48/73), respectively. The median time to achieving CCyR and MMR was 3 months. During follow-up time, the PFS rate was 94.0% (79/83) and the EFS rate was 77.4% (65/83). The most common non-hematological AEs of dasatinib were edema (32.5%), rash itching (18.1%) and fatigue (13.3%). The common hematological AEs of dasatinib were thrombocytopenia (31.3%), leukopenia (19.3%) and anemia (6.0%). Conclusion: Domestic dasatinib was effective and safe as the second-line treatment of CML-CP patients and it can be used as an option for CML-CP patients.
Antineoplastic Agents
;
Dasatinib/therapeutic use*
;
Humans
;
Imatinib Mesylate
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*
;
Protein Kinase Inhibitors
;
Retrospective Studies
;
Treatment Outcome
9.Prognostic significance of early molecular response after second-line treatment with dasatinib of chronic myeloid leukemia patients.
Yi Lin CHEN ; Li MENG ; Guo Lin YUAN ; Zhuang Zhi YANG ; Zhi Ping HUANG ; You Shan ZHANG ; Zhe ZHAO ; Chu Cheng WANG ; Ying BAO ; Hang XIANG ; Hua YIN ; Li Feng CHEN ; Ying Yuan XIONG ; Long WANG ; Wei Ming LI
Chinese Journal of Hematology 2019;40(7):608-611
10.Cancer incidence in patients with type 2 diabetes mellitus in Minhang District of Shanghai
lin Hui XU ; jie Yu YAN ; Hong FANG ; dong Bao YAO ; you Guo QIN ; hong Wang XU ; Fen ZHANG ; Qi GUO ; yan Jun WANG ; Dong-li YUAN ; XU FANG
Fudan University Journal of Medical Sciences 2017;44(5):574-579
Objective To investigate the risk of overall and site-specific cancers in Chinese patients with type 2 diabetes mellitus (T2DM) in Minhang District of Shanghai.Methods A population-based retrospective cohort study including 51 372 T2DM patients was conducted in Minhang District,Shanghai from 2004 to 2014.All T2DM patients were enrolled from the standardized management system based on local electronic information system of Shanghai.Newly-diagnosed cancer cases were identified by record-linkage with the Shanghai Cancer Registry.Standardized incidence ratios (SIR) and 95%CI were used to estimate the risk of cancers among T2DM patients.Results Overall crude incidence rate (CIR) of cancers was 969.69 per 105 person-years in men and 834.17 per 105 person-years in women.The age-standardized rate (ASR [W]) was 206.72 per 105 person-years in men and 285.80 per 105 person-years in women.Increased risk of cancer was found in both sex,with an SIR of 0.93 (95%CI:0.88-0.98) in men and 1.07 (95% CI:1.01-1.12) in women.Conclusions Our results indicate that patients with T2DM may have an increased risk of some cancers,and the increase may vary by sub-sites of cancers.

Result Analysis
Print
Save
E-mail